Clinuvel to commence trial of afamelanotide in the US

By Tim Dean
Tuesday, 30 March, 2010

Melbourne-based biotech, Clinuvel, is set to undertake its first phase II clinical trial in the US of its flagship product, afamelanotide, for the treatment of erythropoietic protoporphyria.

Erythropoietic protoporphyria is a rare condition where sufferers become intolerant to light, resulting in extreme pain and burning of the skin when exposed to normal levels of light. It's estimated to affect 3,000 Americans.

Afamelanotide is an implant that stimulates the production of the body's natural defence against light, melanin, which increases the pigmentation of the skin.

The trial will be held in medical centres in Alabama, California, New York, North Carolina, Texas and Utah.

Afamelanotide has already undergone phase III trials in Europe and Australia, with preliminary results looking positive.

Look out for an in-depth look at Clinuvel and interview with CEO, Dr Philippe Wolgen, in the next issue of Australian Life Scientist.

Related News

'Mini brains' mimic MS myelin damage

The MS organoids give researchers a highly detailed cellular view of myelin destruction...

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd